SPRINGER NATURE

1. Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant

Reactions Weekly (2022)

https://link.springer.com//content/pdf/10.1007%2Fs40278-022-08680-z.pdf

2. The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?

Jaffar A. Al-Tawfiq, Van-Thuan Hoang… in Journal of Epidemiology and Global Health (2022)

https://link.springer.com//content/pdf/10.1007%2Fs44197-022-00032-w.pdf

3. Omicron: a mysterious variant of concern

A. Gowrisankar, T. M. C. Priyanka, Santo Banerjee in The European Physical Journal Plus (2022)

https://link.springer.com//content/pdf/10.1140%2Fepjp%2Fs13360-021-02321-y.pdf

4. The Emergence of Omicron: Challenging Times Are Here Again!

Tanu Singhal in Indian Journal of Pediatrics (2022)

https://link.springer.com//content/pdf/10.1007%2Fs12098-022-04077-4.pdf

5. Role of Omicron variant of SARS-CoV-2 in children in Germany

Stefan Bittmann in World Journal of Pediatrics (2022)

https://link.springer.com//content/pdf/10.1007%2Fs12519-021-00511-3.pdf

6. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant

Maren Schubert, Federico Bertoglio, Stephan Steinke, Philip Alexander Heine… in BMC Medicine (2022)

https://link.springer.com//content/pdf/10.1186%2Fs12916-022-02312-5.pdf

7. Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load

Jorge Quarleri, Veronica Galvan, M. Victoria Delpino in GeroScience (2022)

https://link.springer.com//content/pdf/10.1007%2Fs11357-021-00500-4.pdf

8. Molecular SARS-CoV-2 surveillance in Bavaria shows no Omicron transmission before the end of November 2021

Jennifer Flechsler, Ute Eberle, Alexandra Dangel, Sabrina Hepner, Clara Wimmer… in Infection (2022)

https://link.springer.com//content/pdf/10.1007%2Fs15010-022-01767-1.pdf

9. Impaired detection of omicron by SARS-CoV-2 rapid antigen tests

Andreas Osterman, Irina Badell, Elif Basara… in Medical Microbiology and Immunology (2022)

https://link.springer.com//content/pdf/10.1007%2Fs00430-022-00730-z.pdf

PUBMED

1. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.

Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, Feldman J, Roederer AL, Gregory DJ, Poznansky MC, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB.

Cell. 2022 Feb 3;185(3):457-466.e4. doi: 10.1016/j.cell.2021.12.033. Epub 2022 Jan 6.

PMID: 34995482

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733787/pdf/main.pdf

2. Omicron SARS-CoV-2 variant: What we know and what we don't.

Ferré VM, Peiffer-Smadja N, Visseaux B, Descamps D, Ghosn J, Charpentier C.

Anaesth Crit Care Pain Med. 2022 Feb;41(1):100998. doi: 10.1016/j.accpm.2021.100998. Epub 2021 Dec 10.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660660/pdf/main.pdf

3. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.

Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, Nie J, Wu Q, Qu X, Huang W, Wang Y.

Emerg Microbes Infect. 2022 Dec;11(1):1-5. doi: 10.1080/22221751.2021.2017757.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725892/pdf/TEMI_11_2017757.pdf

4. The Emergence of Omicron: Challenging Times Are Here Again!

Singhal T.

Indian J Pediatr. 2022 Jan 13:1-7. doi: 10.1007/s12098-022-04077-4. Online ahead of print.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756165/pdf/12098_2022_Article_4077.pdf

5. Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021.

Gu H, Krishnan P, Ng DYM, Chang LDJ, Liu GYZ, Cheng SSM, Hui MMY, Fan MCY, Wan JHL, Lau LHK, Cowling BJ, Peiris M, Poon LLM.

Emerg Infect Dis. 2022 Feb;28(2):460-462. doi: 10.3201/eid2802.212422. Epub 2021 Dec 3.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798678/pdf/21-2422.pdf

6. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.

Chen J, Wang R, Gilby NB, Wei GW.

J Chem Inf Model. 2022 Jan 24;62(2):412-422. doi: 10.1021/acs.jcim.1c01451. Epub 2022 Jan 6.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751645/pdf/ci1c01451.pdf

7. Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies.

Kannan SR, Spratt AN, Sharma K, Chand HS, Byrareddy SN, Singh K.

J Autoimmun. 2022 Jan;126:102779. doi: 10.1016/j.jaut.2021.102779. Epub 2021 Dec 13.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666303/pdf/main.pdf

8. Another year another variant: COVID 3.0-Omicron.

Queen D.

Int Wound J. 2022 Jan;19(1):5. doi: 10.1111/iwj.13739.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684846/pdf/IWJ-19-5.pdf

9. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance.

Ren SY, Wang WB, Gao RD, Zhou AM.

World J Clin Cases. 2022 Jan 7;10(1):1-11. doi: 10.12998/wjcc.v10.i1.1.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727245/pdf/WJCC-10-1.pdf

10. Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options.

Mohiuddin M, Kasahara K.

Respir Med. 2022 Jan;191:106716. doi: 10.1016/j.rmed.2021.106716. Epub 2021 Dec 14.

PMID: 34923286

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668234/pdf/main.pdf

11. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.

Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, Kreiss Y, Alroy-Preis S, Regev-Yochay G, Mendelson E, Mandelboim M.

N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823651/pdf/NEJMc2119358.pdf

12. Omicron: a drug developer's perspective.

Fang FF, Shi PY.

Emerg Microbes Infect. 2022 Dec;11(1):208-211. doi: 10.1080/22221751.2021.2023330.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741250/pdf/TEMI_11_2023330.pdf

13. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, Nutalai R, Wang B, Dijokaite A, …

Cell. 2022 Feb 3;185(3):467-484.e15. doi: 10.1016/j.cell.2021.12.046. Epub 2022 Jan 4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723827/pdf/main.pdf

14. From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants.

Papanikolaou V, Chrysovergis A, Ragos V, Tsiambas E, Katsinis S, Manoli A, Papouliakos S, Roukas D, Mastronikolis S, Peschos D, Batistatou A, Kyrodimos E, Mastronikolis N.

Gene. 2022 Mar 10;814:146134. doi: 10.1016/j.gene.2021.146134. Epub 2022 Jan 4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725615/pdf/main.pdf

15. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.

Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, Ip JD, Chan WM, Chu AW, Chan KH, Jin DY, Chen H, Yuen KY, To KK.

Emerg Microbes Infect. 2022 Dec;11(1):277-283. doi: 10.1080/22221751.2021.2023329.

PMID: 34951565

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774049/pdf/TEMI_11_2023329.pdf

SCIENCEDIRECT

1. Fending off Delta - Hospital measures to reduce nosocomial transmission of COVID-19

International Journal of Infectious Diseases, 4 February 2022, Volume 117 (Cover date: April 2022), Pages 139-145

Rachel Hui Fen LIM, Htet Lin HTUN, Angela CHOW
https://www.sciencedirect.com/science/article/pii/S1201971222000777/pdfft?md5=d85f1a6b582b59f45341c331e43c470b&pid=1-s2.0-S1201971222000777-main.pdf

2. Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India
Microbial Pathogenesis, 19 January 2022, Volume 164 (Cover date: March 2022), Article 105404

Pushpendra Singh, Kuldeep Sharma, Nitin M. Nagarkar

https://www.sciencedirect.com/science/article/pii/S0882401022000171/pdfft?md5=ce9a8d3786a0a520ec844bf0b17ab391&pid=1-s2.0-S0882401022000171-main.pdf

3. Modeling and optimal control of mutated COVID-19 (Delta strain) with imperfect vaccination

Chaos, Solitons & Fractals, 31 January 2022, Volume 156 (Cover date: March 2022), Article 111825

Tingting Li, Youming Guo

https://www.sciencedirect.com/science/article/pii/S0960077922000364/pdfft?md5=582b7f8dbf65e45fa1d8f2c343b37011&pid=1-s2.0-S0960077922000364-main.pdf

4. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant–infected patients in Jiangsu, China
International Journal of Infectious Diseases, 19 January 2022, Volume 116 (Cover date: March 2022), Pages 204-209

Zhiliang Hu, Bilin Tao, Jianming Wang

https://www.sciencedirect.com/science/article/pii/S1201971222000339/pdfft?md5=243821a5bcf29c0bf9a2d53fb665e894&pid=1-s2.0-S1201971222000339-main.pdf

5. Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case

Preventive Medicine, 17 November 2021 ,Volume 154 (Cover date: January 2022), Article 106890

Mor Saban, Vicki Myers, Rachel Wilf-Miron
https://www.sciencedirect.com/science/article/pii/S0091743521004631/pdfft?md5=86be23907a1169e9b05113116febfff6&pid=1-s2.0-S0091743521004631-main.pdf

6. Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study

The Lancet Regional Health - Europe, 28 October 2021, Volume 12 (Cover date: January 2022), Article 100252

Hester Allen, Amoolya Vusirikala, Meaghan Kall

https://www.sciencedirect.com/science/article/pii/S2666776221002386/pdfft?md5=d8ead76b2c31b593bf4284237a84cef1&pid=1-s2.0-S2666776221002386-main.pdf

7. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study

The Lancet Respiratory Medicine, Available online 25 February 2022, In press, corrected proof

Paul M McKeigue, David A McAllister, Helen M Colhoun
https://www.sciencedirect.com/science/article/pii/S2213260022000455/pdfft?md5=0879a789fe5fe944a329e8e64ec23c6e&pid=1-s2.0-S2213260022000455-main.pdf

8. Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas

The American Journal of Pathology, 11 November 2021, Volume 192, Issue 2 (Cover date: February 2022), Pages 320-331

Paul A. Christensen, Randall J. Olsen, James M. Musser

https://www.sciencedirect.com/science/article/pii/S0002944021004806/pdfft?md5=54059817be9e9c7d408a640ff6e90819&pid=1-s2.0-S0002944021004806-main.pdf

9. Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
Mayo Clinic Proceedings, 16 December 2021, Volume 97, Issue 2 (Cover date: February 2022), Pages 327-332

John C. O’Horo, Douglas W. Challener, Raymund R. Razonable

https://www.sciencedirect.com/science/article/pii/S0025619621009241/pdfft?md5=1cadf5f488530d03a2ad4dddaf8c3ae1&pid=1-s2.0-S0025619621009241-main.pdf

10. Rapid detection of the widely circulating B.1.617.2 (Delta) SARS-CoV-2 variant
Pathology ,Available online 31 January 2022, In press, corrected proof

Adriana E. Rosato, Engy Msiha, Roberto R. Rosato

https://www.sciencedirect.com/science/article/pii/S0031302522000356/pdfft?md5=ca8997c9cc9944ab4fbd2a19b85de64c&pid=1-s2.0-S0031302522000356-main.pdf

11. Contact tracing period and epidemiological characteristics of an outbreak of the SARS-CoV-2 Delta variant in Guangzhou
International Journal of Infectious Diseases, 29 January 2022, Volume 117 (Cover date: April 2022), Pages 18-23

Xiaowei Ma, Keyi Wu, Xianbo Wu

https://www.sciencedirect.com/science/article/pii/S1201971222000364/pdfft?md5=c24edc9db32a52842d0f417ba3de8a3b&pid=1-s2.0-S1201971222000364-main.pdf

12. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants

eBioMedicine, 17 December 2021, Volume 75 (Cover date: January 2022), Article 103761

Rüdiger Groß, Michelle Zanoni, Janis A. Müller

https://www.sciencedirect.com/science/article/pii/S2352396421005557/pdfft?md5=84752304812a2d77efbff57e2892aa85&pid=1-s2.0-S2352396421005557-main.pdf

13. Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

Clinical Microbiology and Infection, Available online 3 February 2022, In press, corrected proof

Louise Benning, Christian Morath, Claudius Speer

https://www.sciencedirect.com/science/article/pii/S1198743X22000350/pdfft?md5=23056daf8465068b4189dc1179fc96d9&pid=1-s2.0-S1198743X22000350-main.pdf

14. SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant

Infectious Disease Clinics of North America, Available online 1 February 2022, In press, journal pre-proof

Eric A. Meyerowitz, Aaron Richterman

https://www.sciencedirect.com/science/article/pii/S0891552022000174/pdfft?md5=5d16ecc1cb84b36e711af7e2d70a1139&pid=1-s2.0-S0891552022000174-main.pdf

15. Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike – ACE2 complexes reveal distinct changes between both variants

Computational and Structural Biotechnology Journal, 26 February 2022, Volume 20 (Cover date: 2022), Pages 1168-1176

Eileen Socher, Lukas Heger, Philipp Arnold

https://www.sciencedirect.com/science/article/pii/S2001037022000551/pdfft?md5=be588312d3378f3e5d71bd78c97bde04&pid=1-s2.0-S2001037022000551-main.pdf

16. Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations

The Lancet Regional Health - Americas, 25 November 2021, Volume 5 (Cover date: January 2022), Article 100133

Jennifer R. Head, Kristin L. Andrejko, Justin V. Remais

https://www.sciencedirect.com/science/article/pii/S2667193X21001290/pdfft?md5=288c40f9ebeca1e72f60b14b74d70cb7&pid=1-s2.0-S2667193X21001290-main.pdf

WILEY

1. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach

Dr. Milan Sencanski,Dr. Vladimir Perovic,Dr. Jelena Milicevic,Dr. Tamara Todorovic,Dr. Radivoje Prodanovic,Dr. Veljko Veljkovic,Dr. Slobodan Paessler,Dr. Sanja Glisic

First published: 01 February 2022

https://chemistry-europe.onlinelibrary.wiley.com/doi/epdf/10.1002/open.202100248

2. Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation

Liang-Chang Hu,Chuan-Hua Ding,Hong-Ying Li,Zhen-Zhen Li,Ying Chen,Li-Peng Li,Wan-Zhong Li,Wen-Shan Liu

First published: 06 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1111/jfbc.14085

3. SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion

Federica Quaglia,Edoardo Salladini,Marco Carraro,Giovanni Minervini,Silvio C.E. Tosatto,Philippe Le Mercier

First published: 02 February 2022

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/febs.16379

4. Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies

Adam J. Kanack PhD,Bandana Singh PhD,Gemlyn George MBBS,Krishna Gundabolu MBBS MS,Scott A. Koepsell MD PhD,Mouhamed Yazan Abou-Ismail MD,Karen A. Moser MD

First published: 07 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.26488

5. A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2

Ismail Celik,Trina E. Tallei

First published: 07 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcb.30226

6. Multisystem screening reveals SARS-CoV-2 in neurons of the myenteric plexus and in megakaryocytes

Sandra Gray-Rodriguez,Melanie P. Jensen,Maria Otero-Jimenez,Brian Hanley,Olivia C. Swann,Patrick A. Ward,Francisco J. Salguero,Nadira Querido,Ildiko Farkas,Elisavet Velentza-Almpani …

First published: 02 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/path.5878

7. Successful Early Use of Anti-SARS-CoV-2 Monoclonal Neutralizing Antibodies in SARS-CoV-2 Infected Hematological Patients – A Czech Multicenter Experience

Barbora Weinbergerová,Ivo Demel,Benjamin Víšek,Jan Válka,Martin Čerňan,Pavel Jindra,Jan Novák,Lukáš Stejskal,Flóra Kovácsová,Tomáš Kabut,Tomáš Szotkowski,Roman Hájek …

First published: 04 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2974

8. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant

Dandan Tian,Yanhong Sun,Huihong Xu,Qing Ye

First published: 03 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27643

9. Comparing humoral immune response to SARS-CoV2 vaccines in multiple sclerosis and healthy controls: an Austrian prospective multi-center cohort study

Gabriel Bsteh,Harald Hegen,Gerhard Traxler,Nik Krajnc,Fritz Leutmezer,Franziska Di Pauli,Barbara Kornek,Paulus Rommer,Gudrun Zulehner,Sophie Dürauer,Angelika Bauer …

First published: 01 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.15265

10. Clinical impact and benefits of a simultaneous cardio-pulmonary rehabilitation in a COVID-19-infected patient following cardiac arrest: A case report

Mirim Lee,Jeong Jae Lee,Jun young Ko,Yong Kyun Kim,Seungbok Lee

First published: 02 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/ccr3.5345

Các công bố về COVID-19 trước thời gian trên:

Cập nhật các công bố về COVID-19 từ ngày 25/03 đến ngày 04/03/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nhung-nghien-cuu-phan-tich-ve-covid-19-ngay-25-2-4-3-2022-4729.html

Cập nhật các công bố về COVID-19 từ ngày 18/02 đến ngày 25/02/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/vac-xin-covid-19-va-nhung-xu-huong-nghien-cuu-ngay-18-2-25-2-2022-4707.html

Cập nhật các công bố về COVID-19 từ ngày 11/02 đến ngày 18/02/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/covid-19-va-nhung-tac-dong-doi-voi-doi-song-ngay-11-18-2-2022-4685.html

Cập nhật các công bố về COVID-19 từ ngày 04/02 đến ngày 11/02/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nghien-cuu-moi-ve-covid-19-tu-ngay-4-2-den-ngay-11-2-2022-4664.html